Table 1.
Baseline characteristics of the participants.
| Baseline characteristics | Before matching |
After 1:1 propensity-score matching |
||||
|---|---|---|---|---|---|---|
| Azvudine (n = 245) | Controls (n = 722) | SMD | Azvudine (n = 245) | Matched controls (n = 245) | SMD | |
| Age (years), mean (SD) | 69.13 (13.4) | 66.89 (14.8) | 0.159 | 69.13 (13.4) | 69.25 (14.0) | 0.022 |
| Sex, n (%) | 0.079 | 0.025 | ||||
| Men | 154 (62.9) | 426 (59.0) | 154 (62.9) | 157 (64.1) | ||
| Women | 91 (37.1) | 296 (41.0) | 91 (37.1) | 88 (35.9) | ||
| COVID-19 vaccination status | 0.010 | 0.016 | ||||
| Vaccinated | 118 (48.2) | 344 (47.6) | 118 (48.2) | 120 (49.0) | ||
| Unknown | 127 (51.8) | 378 (52.4) | 127 (51.8) | 125 (51.0) | ||
| Time from symptom onset to admission, n (%) | 0.334 | 0.012 | ||||
| 0–5 days | 214 (87.3) | 537 (74.4) | 214 (87.3) | 215 (87.8) | ||
| >5 days | 31 (12.7) | 185 (25.6) | 31 (12.7) | 30 (12.2) | ||
| Severity at admission, n (%) | 0.189 | 0.060 | ||||
| Non-severe | 88 (35.9) | 196 (27.1) | 88 (35.9) | 81 (33.1) | ||
| Severe | 157 (64.1) | 526 (72.9) | 157 (64.1) | 164 (66.9) | ||
| Concomitant treatments initiated at admission, n (%) | ||||||
| Systemic steroid | 64 (26.1) | 152 (21.1) | 0.119 | 64 (26.1) | 56 (22.9) | 0.076 |
| Antibiotics | 130 (53.1) | 265 (36.7) | 0.333 | 130 (53.1) | 138 (56.3) | 0.065 |
| Immunomodulators | 25 (10.2) | 57 (7.9) | 0.080 | 25 (10.2) | 22 (9.0) | 0.042 |
SMD, Standard mean difference.